Acute Toxicological Profile of Pharmaceutical-Grade Nicotinamide Riboside: A Route-Dependent Assessment Across Intravenous, Intramuscular, and Subcutaneous Administration

This study establishes that pharmaceutical-grade nicotinamide riboside chloride exhibits route-dependent acute toxicity in rats, with intravenous administration showing an estimated LD50 of approximately 2000 mg/kg while intramuscular and subcutaneous routes demonstrated LD50 values exceeding 2000 mg/kg.

The Gist

The "Speed vs. Safety" Test: How the Body Handles Nicotinamide Riboside

Imagine Nicotinamide Riboside (NR) as a high-performance fuel for your body's cells. It's a vitamin-like substance that helps power your energy engines. Most people take this fuel as a pill (oral), where it has to travel through the digestive system, get filtered by the liver, and then slowly enter the bloodstream. It's like driving a car through heavy city traffic to get to your destination.

But what if you could bypass the traffic and inject the fuel directly into the engine? That's what parenteral administration (injections) does. However, just because you can inject something doesn't mean it's safe to do so at any speed or in any way.

This study was like a safety crash test for a new type of fuel injection. The researchers wanted to see: If we shoot this fuel directly into the blood (IV), into the muscle (IM), or under the skin (SC), how much is too much before it becomes dangerous?

They tested this on rats using a clever "Up-and-Down" game of "Goldilocks" to find the exact tipping point where the substance becomes lethal.

---

The Three Routes: A Tale of Three Delivery Methods

The researchers treated the rats like delivery trucks, testing three different ways to drop off the cargo:

1. The "Bullet Train" (Intravenous / IV)

The Method: Shoving the entire dose directly into the tail vein in one giant, fast gulp.
The Result: Dangerous at high speeds.
When they tried to deliver a massive dose (2000 mg/kg) all at once, the rats' bodies couldn't handle the shock. Two out of three rats died almost immediately.

• The Analogy: Imagine trying to drink a whole swimming pool of water in one second. Even if the water is safe, your stomach (or in this case, the blood vessels) can't handle the sudden flood. The pressure was too high, and the system crashed.
• Side Effects: The surviving rats at high doses got "tail rot"—their tails turned black and fell off. This suggests the fuel was so concentrated it burned the tiny blood vessels in the tail.
• The Verdict: The "Lethal Dose" (the point where half the animals would die) is around 2000 mg/kg, but it's risky. The body needs time to process this fuel, not a sudden explosion of it.

2. The "Slow Leak" (Subcutaneous / SC)

The Method: Injecting the fuel under the skin (like a vaccine or insulin shot).
The Result: Safe for the body, but rough on the skin.
Even at the highest dose (2000 mg/kg), no rats died. The fuel trickled into the system slowly, so the body wasn't shocked.

• The Analogy: This is like a slow leak in a tire. The air (fuel) gets in, but it doesn't blow the tire out. However, if you pour too much oil on a patch of grass, the grass gets irritated.
• Side Effects: The rats got angry at the injection site. Their skin turned black, got sore, and they scratched themselves because it hurt.
• The Verdict: The body is fine with this amount, but the skin isn't. The "safe dose" for humans would be lower just to avoid a painful, angry injection site.

3. The "Deep Dive" (Intramuscular / IM)

The Method: Injecting the fuel deep into the thigh muscle.
The Result: The Goldilocks Zone.
This was the clear winner. Even at the highest dose (2000 mg/kg), zero rats died, and they had no side effects at all.

• The Analogy: Imagine dropping a heavy stone into a deep, soft pile of sand. The stone sinks in, but the sand absorbs the impact perfectly. The muscle acted like a sponge, soaking up the fuel and releasing it slowly and gently.
• The Verdict: This is the safest way to inject this fuel. The body handled the massive dose without blinking.

---

What Does This Mean for Humans?

The researchers did some math to translate these rat results into human terms (using body surface area scaling, like converting miles to kilometers).

• If you inject it into a vein (IV): You have to be very careful. If you push it in too fast (like a bolus), it could be fatal. In the real world, doctors would likely drip it in slowly over 20–30 minutes to avoid the "flood" effect.
• If you inject it under the skin (SC): It's safe from a life-threatening perspective, but you might get a sore, irritated bump.
• If you inject it into the muscle (IM): This looks like the safest bet. You could theoretically give a huge dose, and the body would handle it like a champ.

The Big Takeaway

The main lesson here is that how you deliver a medicine is just as important as what the medicine is.

Think of Nicotinamide Riboside like a spicy sauce.

• Oral (Pill): You eat a spoonful. It's fine.
• IV (Direct to blood): You shoot a whole bottle into your bloodstream. Your body screams "Too much, too fast!" and shuts down.
• IM (Muscle): You pour it into a deep bowl of rice (the muscle). It mixes perfectly, and you enjoy the flavor without burning your mouth.

This study tells scientists that if they want to use this vitamin as an injection in the future, hitting the muscle is the safest route, and if they must use the vein, they need to slow the drip down significantly to avoid a toxic shock.

Technical Summary

1. Problem Statement

Nicotinamide Riboside Chloride (NR-Cl), marketed as Niagen®, is a well-established oral precursor to Nicotinamide Adenine Dinucleotide (NAD+), recognized as Generally Recognized as Safe (GRAS) with an oral LD50 exceeding 5000 mg/kg in rodents. However, there is a significant lack of toxicological data regarding parenteral administration (intravenous, intramuscular, and subcutaneous).

• The Gap: While oral delivery involves first-pass metabolism, parenteral routes bypass this, potentially leading to different pharmacokinetic profiles, higher peak concentrations, and unique toxicity risks.
• The Need: To support future clinical research and therapeutic development involving injectable NR-Cl, it is necessary to establish route-specific acute toxicity benchmarks, specifically the Median Lethal Dose (LD50) and No Observed Adverse Effect Levels (NOAEL), as extrapolation from oral data is insufficient.

2. Methodology

The study employed a rigorous, GLP-compliant experimental design adapted from OECD Guideline 425 (Up-and-Down Procedure), modified for parenteral routes.

• Test Article: Pharmaceutical-grade $\beta$-nicotinamide riboside chloride (NiagenPlus®), purity >98.9%, dissolved in 0.9% normal saline.
• Subjects: Healthy female Sprague-Dawley rats (8–12 weeks old, 210–277 g). Females were selected for their known sensitivity in toxicity testing.
• Study Design: Three independent studies (IV, IM, SC) conducted at Adgyl Lifesciences (India).
  • Dosing Strategy: Sequential dosing with ~48-hour intervals.
  • Starting Dose: 650 mg/kg.
  • Progression: Doses increased by a factor of 1.5 (650 → 910 → 1260 → 2000 mg/kg) based on survival outcomes.
  • Stopping Criteria: Three consecutive survivors at the limit dose (2000 mg/kg) or derivation of an LD50 estimate.
• Administration Routes:
  • Intramuscular (IM): 0.5 mL/kg split bilaterally into quadriceps femoris.
  • Intravenous (IV): 5 mL/kg bolus via tail vein.
  • Subcutaneous (SC): 5 mL/kg split into two sites in the cervical region.
• Observations: 14-day monitoring for mortality, clinical signs (behavior, necropsy), bodyweight changes, and gross pathology.
• Analysis: LD50 and 95% confidence intervals calculated using AOT425StatPgm software. Human Equivalent Doses (HED) were derived using FDA body surface area scaling.

3. Key Results

A. Intramuscular (IM) Administration

• Mortality: 0% at all tested doses (up to 2000 mg/kg).
• Clinical Signs: No adverse clinical signs or bodyweight suppression observed.
• Pathology: No treatment-related lesions or abnormalities found during necropsy.
• Outcome:
  • LD50: >2000 mg/kg.
  • NOAEL: ≥2000 mg/kg.

B. Subcutaneous (SC) Administration

• Mortality: 0% at all tested doses (up to 2000 mg/kg).
• Clinical Signs: No systemic toxicity. However, local injection site reactions were observed starting at 910 mg/kg, characterized by skin discoloration (brown/black), wound reactions, and self-inflicted scratching.
• Pathology: Necropsy confirmed local tissue irritation (discoloration, reaction at wound site) but no systemic pathology.
• Outcome:
  • LD50: >2000 mg/kg.
  • NOAEL: 650 mg/kg (highest dose with no local reactions).

C. Intravenous (IV) Administration

• Mortality: Observed at the limit dose (2000 mg/kg). Two out of three animals administered 2000 mg/kg died immediately (within 1 minute) following recumbency.
• Clinical Signs:
  • 1260–2000 mg/kg: Surviving animals exhibited severe tail discoloration (brown to black) progressing to tail detachment (necrosis) within 12–15 days.
  • 2000 mg/kg (Fatal): Immediate recumbency and death.
• Pathology: No systemic gross pathological abnormalities found in deceased animals; tail lesions were localized to the injection site.
• Outcome:
  • Calculated LD50: ~2000 mg/kg (95% CI: 1319–5910 mg/kg).
  • Conservative LD50 Range: 1260–2000 mg/kg.
  • NOAEL: 910 mg/kg (highest dose with no mortality or clinical signs).

D. Human Equivalent Dose (HED) Translation

Using body surface area scaling (Rat Km=6, Human Km=37):

• IM/SC LD50: >324 mg/kg (>23 g for a 70 kg human).
• IV NOAEL: 147 mg/kg (10 g for a 70 kg human).
• IV Conservative LD50 Range: 204–324 mg/kg (14–23 g for a 70 kg human).

4. Key Contributions

1. First Systematic Parenteral Toxicity Profile: This study provides the first comprehensive LD50 data for pharmaceutical-grade NR-Cl across three parenteral routes, filling a critical gap in the literature.
2. Route-Dependent Toxicity Demonstration: It conclusively demonstrates that toxicity is not inherent to the molecule alone but is heavily dependent on the route of administration and absorption kinetics.
   • IM and SC routes showed high tolerability (LD50 >2000 mg/kg).
   • IV route showed significantly higher acute lethality (LD50 ~2000 mg/kg) and local vascular toxicity.
3. Mechanistic Insight: The authors propose that IV mortality and tail necrosis are likely driven by high peak plasma concentrations and osmotic stress from rapid bolus delivery (concentrations of 252–400 mg/mL), rather than intrinsic chemical toxicity.
4. Methodological Adaptation: Successfully adapted the OECD 425 Up-and-Down procedure (originally for oral gavage) to parenteral routes, providing a framework for future non-oral acute toxicity studies.

5. Significance and Implications

• Clinical Safety Benchmarks: The data establishes a safety foundation for developing injectable NR-Cl therapies. The NOAELs provide starting points for Phase I clinical trials.
• Formulation Guidance: The findings suggest that slow infusion (rather than rapid bolus) is critical for IV administration to mitigate vascular stress and mortality. Clinical protocols should likely avoid high-concentration bolus injections.
• Route Selection:
  • IM appears to be the safest route with the widest therapeutic window.
  • SC is safe systemically but requires dose splitting or lower concentrations to avoid local tissue irritation.
  • IV requires strict control over infusion rates and concentrations to prevent acute vascular toxicity.
• Future Research: The study highlights the need for pharmacokinetic studies to correlate peak plasma concentrations (Cmax) with adverse events and to investigate whether slower infusion rates in humans can eliminate the mortality observed in the rat bolus model.

Conclusion: Pharmaceutical-grade NR-Cl is safe via IM and SC routes at doses up to 2000 mg/kg. IV administration carries acute risks of mortality and local vascular injury at high doses, likely due to rapid bolus delivery. These findings necessitate route-specific safety assessments and careful dosing strategies for future clinical applications.